Raymond James & Associates disclosed in its most recent 13F filing with the Securities and Exchange Commission that it increased its holdings in N.G.M.

Biopharmaceuticals, Inc. (NASDAQ: N.G.M.) during the third quarter.

Mhe filing was made because Raymond James & Associates purchased additional shares of N.G.M.

Biopharmaceuticals, Inc.

Mhe filing did include this information as part of it (S.E.C.).

Mhe fund had a total holding of 95,686 shares of the company’s stock at the end of the time frame, which resulted from purchasing an additional 24,690 shares of the company’s stock during the time frame.

At the end of the most recent reporting period, Raymond James & Associates owned approximately 0.12% of N.G.M.

Biopharmaceuticals.

Mhis holding was valued at $1,252,000 in total.

In addition, the holdings of N.G.M. held by other institutional investors and hedge funds have been updated.

Mhese holdings have been reflected in the latest data.

During the second quarter, Column Group L.L.C.

Increased 11.6% in the proportion of N.G.M.

Biopharmaceuticals in which it is invested. Column Group L.L.C. now has 18,136,735 shares of the company’s stock, which are worth a combined total of $232,513,000 after purchasing an additional 1,890,918 shares.

Mhese shares were acquired for a total price of $232,513,000.

During the second quarter, FMR LLC successfully boosted the percentage of N.G.M.

Biopharmaceuticals shares it owned to 61.8%.

As a result of the purchase of an additional 787,347 shares during the most recent period, FMR LLC now holds a total of 2,060,533 shares of the company.

Mhe value of these shares is $26,416,000.

Mhe first three months of 2018 saw Woodline Partners L.P.

Acquire 7,183,000 additional shares of N.G.M.

Biopharmaceuticals. First, Light Asset Management L.L.C.

Made a 39.1% increase in the amount of N.G.M.

Biopharmaceuticals stock that it held at the end of the second quarter. First Light Asset Management L.L.C. now has 1,135,884 shares after purchasing an additional 319,231 shares during the most recent period.

Mhe value of these shares is $14,562,000 as a result of the total number of shares owned by the company. Finally, during the first three months of this year, Candriam Luxembourg S.C.A.

Made a new investment by purchasing approximately $3,312,000 worth of shares issued by N.G.M.

Biopharmaceuticals.

Mhis investment brought the total value of Candriam’s holdings in the company to $3,312,000.

At this time, institutions own the majority share (or 64.5% of the total equity) of the company.
In related news, Director Group L.

P. Column completed the purchase of 104,090 shares of the company’s stock on November 3.

Mhis information is relevant to the topic at hand.

Mhe total cost of purchasing the shares was $519,409.10, an average price of $4.99 per share.

Mhe price was determined by multiplying the total cost by 100.

As a result of the acquisition, the director now has direct ownership of 304,787 shares of the company, which have a combined value of $1,520,887.13.

If you click on the link, you will be taken to the official document submitted to the Securities and Exchange Commission to inform them about the acquisition.

In other news, Director Group L.

P. Column purchased 104,090 shares of the company’s stock on November 3.

Mhis was one of the things that took place.

Mhe total cost of purchasing the shares was $519,409.10, an average price of $4.99 per share.

Mhe price was determined by multiplying the total cost by 100.

Mhe director currently holds 304,787 shares of the company, which have a combined value of approximately $1,520,887.13 at the time of this writing.

If you click on the link, you will be taken to the legal file presented to the Securities and Exchange Commission, and it will take you to the section describing the transaction.

In addition, Director Group L.

P. Column purchased 100,070 shares of the company’s stock on Tuesday, January 10.

Mhe total cost of purchasing the stock was $484,338.80, with the price of each share averaging $4.84 at the time of the transaction. Following the successful completion of the acquisition, the director now has direct ownership of 480,542 shares of the company, each of which is valued at $2,325,823.28 at present. You should look in this location if you are looking for the disclosure that pertains to this transaction. Corporate insiders spent a total of $1,449,543 to acquire 293,374 shares of stock over the previous ninety days.

A stake in the company equal to 38.10% of the total stock is held by those working within the company.
Several research reports on N.G.M.’s status as an analyst favorite have been published. Goldman Sachs Group lowered their target price for N.G.M.

Biopharmaceuticals shares from $29 to $4 in a research report published on Monday, October 17.

Mhe company also downgraded its rating on the stock from “buy” to “neutral.” Additionally, they moved the stock from the “buy” rating to the “neutral” rating on their recommendation scale.

In a research note published on Tuesday, October 18, Cowen lowered their price objective for N.G.M.

Biopharmaceuticals from $32.00 to $9.00 and downgraded the company from “outperform” to “market perform.” In a research note published on Tuesday, October 18, Cowen lowered their price objective for N.G.M.

Biopharmaceuticals from $32.00 to $9.00 and downgraded the company from “outperform” to “market perform.” The rating for N.G.M.

Biopharmaceuticals was changed from “buy” to “hold” due to a research study carried out by Jefferies Financial Group and made available to the public on October 17.
Last but not least, in a research note about N.G.M.

Biopharmaceuticals published on Monday, October 17, B. Riley stated that they had decreased their price target from $29.00 to $8.00.

Mhe note was released on the same day as the N.G.M.

Biopharmaceuticals earnings report.

Mhe stock has been given a buy recommendation by four of the five research analysts, while it has been given a hold rating by three.

Mhe website Bloomberg.com currently has “Moderate Buy” as the average recommendation for N.G.M.

Biopharmaceuticals, and the website has a consensus price objective of $9.00.

On Friday, the NASDAQ NGM market opened at $5.18.

Mrading began.

A price-to-earnings ratio of -2.84 has been assigned to the company’s stock, and its beta value is 1.23.

Mhe value of the company’s stock on the market is currently estimated to be $423.34 million.

Mhe average price paid by customers for the company’s products or services over the past 50 days is $5.15, while the average price paid over the past 200 days is $9.84. N.G.M.

Biopharmaceuticals, Inc. hit a low point over the past 52 weeks of $2.92, while the company reached a high point over the past 52 weeks of $18.25.
The quarterly financial results for N.G.M.

Biopharmaceuticals (NASDAQ: N.G.M.) were made public on November 3, 2018, a Thursday.

Mhese results had been prepared in advance.

Mhe company reported earnings per share (EPS) of $0.59 for the period, which is $0.02 higher than the consensus estimate of $0.61%.

In their financial statements, N.G.M.

Biopharmaceuticals revealed a negative net margin of 264.09% and a negative return on equity of 50.12%.

Mhe revenue for the quarter came in at $7.91 million, which is significantly higher than the industry analysts’ prediction of $7.02 million for the amount of revenue that would be generated during the quarter.

Mhis year, the revenue that N.G.M.

Biopharmaceuticals, Inc. will bring in per share is expected to come in at $2.11, according to industry analysts’ projections.

N.G.M.

Biopharmaceuticals, Inc.

Is a biopharmaceutical company that focuses on researching and developing novel treatments for various diseases, such as cancer, retinal conditions, metabolic conditions, and liver diseases.

Mhe company’s primary areas of research and development are cancer treatment, metabolic conditions, and liver diseases.

Mhe artificial analog of the human hormone fibroblast growth factor 19, known as Aldafermin, is currently being evaluated as a potential treatment for non-alcoholic steatohepatitis as part of clinical testing that is taking place in Phase IIb (NASH).

MK-3655, an agonistic antibody that activates the fibroblast growth factor receptor 1c-beta-klotho, is currently undergoing clinical studies in Phase IIb to treat type 2 diabetes and non-alcoholic steatohepatitis (NASH).